Blocknomi
TLDR An oral GLP-1 medication from Novo Nordisk achieved its primary endpoint in a phase 3 study enrolling young type 2 diabetes patients The medication demonstrated a 0.83 percentage point…
Related articles
-
Ethereum risks 10% decline versus Bitcoin despite record ETH staking
Cointelegraph Published 22.04.2026 17:19
-
Zcash (ZEC) Price Prediction: Can Support at $300 Fuel the Next Move Toward $400?
BlockchainReporter Published 13.04.2026 09:33
-
XRP Integration: Rakuten Brings Ripple Payments to 44 Million Japanese Consumers
Blocknomi Published 15.04.2026 06:57
-
Iran denies reports of crypto tolls in Strait of Hormuz
Crypto.News Published 23.04.2026 15:14
-
Amazon (AMZN) Stock Surges 20% in April as Cramer Favors It Over Microsoft (MSFT)
Blocknomi Published 19.04.2026 08:30
-
Goldman Sachs Targets BTC Yield With New Bitcoin Income ETF
BeInCrypto Published 14.04.2026 19:00
-
XRP Price Prediction: $1.55 Target Could Ignite Markets While Pepeto Looks Like The Smarter Entry
Blocknomi Published 21.04.2026 01:58
-
Crypto Ownership in Denmark Flat at 4% Despite Global Hype
Bitcoin.com Published 16.04.2026 09:15